Another consideration would be to evaluate the combination of pevonedistat with “second-generation” BTK inhibitors (e.g., acalabrutinib, zanubrutinib) which may further mitigate the risks of bleeding and atrial fibrillation. This evidence concerns the gene BTK and atrial fibrillation.